Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2006 December;50(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2006 December;50(4):296-309

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

ADVANCES IN RADIONUCLIDE THERAPY  


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2006 December;50(4):296-309

language: English

Vascular tumor targeting

Ahlskog J. 1, Paganelli G. 2, Neri D. 1

1 Institute of Pharmaceutical Sciences ETH Zurich, Zurich, Switzerland
2 European Institute of Oncology, Milan, Italy


FULL TEXT  


The growth of solid tumors is dependent on their capacity to acquire blood supply. Therefore, much effort has been directed towards the development of anti-angiogenic agents which inhibit the process of neovascularization. More recently, it has become apparent that the targeted destruction of the established tumor vasculature represents a complementary avenue for growing therapeutic opportunities. This review provides evidence that vascular tumor targeting is an effective anti-tumor strategy in animal models. It further describes strategies for the identification of putative tumor vascular targets and discusses future prospects for vascular targeting applications in the clinical setting.

top of page

Publication History

Cite this article as

Corresponding author e-mail